These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 6379981)

  • 1. A survey of surface hemorheological experiments on the inhibition of fibrinogenin formation employing surface layers of fibrinogen systems with heparins and other substances. A contribution on antithrombogenic action.
    Copley AL; King RG
    Thromb Res; 1984 Aug; 35(3):237-56. PubMed ID: 6379981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the antithrombogenic action of low molecular weight heparins and of chondroitins A, B and C.
    Copley AL; King RG; Chien S
    Biorheology; 1983; 20(5):697-704. PubMed ID: 6428487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemorheological studies of the effect of heparin on the course of coagulation.
    Overholser KA; Baysinger CB; Harris TR; Deveau T
    Thromb Haemost; 1976 Apr; 35(2):447-59. PubMed ID: 989642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombin-independent effects of heparins on fibrin clot nanostructure.
    Yeromonahos C; Marlu R; Polack B; Caton F
    Arterioscler Thromb Vasc Biol; 2012 May; 32(5):1320-4. PubMed ID: 22362760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo effects of low molecular weight heparins on experimental thrombosis and bleeding.
    Hirsh J
    Haemostasis; 1986; 16(2):82-6. PubMed ID: 3710297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin from bovine intestinal mucosa: glycans with multiple sulfation patterns and anticoagulant effects.
    Tovar AM; Capillé NV; Santos GR; Vairo BC; Oliveira SN; Fonseca RJ; Mourão PA
    Thromb Haemost; 2012 May; 107(5):903-15. PubMed ID: 22437650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin.
    Olson ST; Swanson R; Raub-Segall E; Bedsted T; Sadri M; Petitou M; Hérault JP; Herbert JM; Björk I
    Thromb Haemost; 2004 Nov; 92(5):929-39. PubMed ID: 15543318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralisation of the anti-coagulant effects of heparin by histones in blood plasma and purified systems.
    Longstaff C; Hogwood J; Gray E; Komorowicz E; Varjú I; Varga Z; Kolev K
    Thromb Haemost; 2016 Mar; 115(3):591-9. PubMed ID: 26632486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An approach to assigning in vitro potency to unfractionated and low molecular weight heparins based on the inhibition of prothrombin activation and catalysis of thrombin inhibition.
    Ofosu FA; Smith LM; Anvari N; Blajchman MA
    Thromb Haemost; 1988 Oct; 60(2):193-8. PubMed ID: 2851191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of thrombin-receptors of thrombocytes for the interaction of heparins and low-molecular-weight heparin in human whole blood clotting.
    Harenberg J; Schuler M; Zimmermann R; Heptner W
    Haemostasis; 1988; 18 Suppl 3():20-2. PubMed ID: 2840370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An accessory to the Weissenberg rheogoniometer for the measurement of viscoelasticity of surface layers of protein solutions.
    King RG; Copley AL
    Biorheology; 1973 Dec; 10(4):541-3. PubMed ID: 4783685
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of heparin on the viscoelasticity of whole blood clots.
    Overholser KA; Itin JP; Brown DR; Harris TR
    Biorheology; 1975 Aug; 12(5):309-16. PubMed ID: 1203534
    [No Abstract]   [Full Text] [Related]  

  • 13. Mechanisms for the anticoagulant effect of heparin and related polysaccharides.
    Ofosu FA
    Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological actions of sulodexide.
    Ofosu FA
    Semin Thromb Hemost; 1998; 24(2):127-38. PubMed ID: 9579633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment by transient elastography of the viscoelastic properties of blood during clotting.
    Gennisson JL; Lerouge S; Cloutier G
    Ultrasound Med Biol; 2006 Oct; 32(10):1529-37. PubMed ID: 17045874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New targets for antithrombotic drugs.
    Thiagarajan P
    Am J Cardiovasc Drugs; 2002; 2(4):227-35. PubMed ID: 14727968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The anticoagulant properties of mast cell product, chondroitin sulphate E.
    Scully MF; Ellis V; Seno N; Kakkar VV
    Biochem Biophys Res Commun; 1986 May; 137(1):15-22. PubMed ID: 3087353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Change of viscoelastic property and morphology of fibrin affected by antithrombin III and heparin: QCM-Z and AFM study.
    Jung H; Tae G; Kim YH; Johannsmann D
    Colloids Surf B Biointerfaces; 2009 Jan; 68(1):111-9. PubMed ID: 19004623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coagulation protein function VI: augmentation of anticoagulant function by acetaldehyde-treated heparin.
    Brecher AS; Hellman K; Basista MH
    Dig Dis Sci; 1999 Jul; 44(7):1349-55. PubMed ID: 10489917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of dextran sulphates on thrombin activity.
    Suzuki K; Hashimoto S
    J Clin Pathol; 1979 May; 32(5):439-44. PubMed ID: 469001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.